The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 19, 2017
Filed:
Jun. 20, 2016
Applicant:
Regenerative Medical Solutions, Inc., Chicago, IL (US);
Inventors:
Xiaofang Xu, Park Ridge, IL (US);
Jon Odorico, Park Ridge, IL (US);
Erik Forsberg, Park Ridge, IL (US);
Amber A. Mael, Madison, WI (US);
Assignee:
REGENERATIVE MEDICAL SOLUTIONS, INC., Chicago, IL (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
G01N 33/50 (2006.01); C12N 5/071 (2010.01); A61K 35/39 (2015.01); A61K 9/16 (2006.01); A61K 45/06 (2006.01); A61K 9/50 (2006.01); A61K 35/545 (2015.01);
U.S. Cl.
CPC ...
C12N 5/0676 (2013.01); A61K 9/1652 (2013.01); A61K 9/5036 (2013.01); A61K 35/39 (2013.01); A61K 45/06 (2013.01); G01N 33/507 (2013.01); A61K 35/545 (2013.01); C12N 2500/05 (2013.01); C12N 2500/22 (2013.01); C12N 2500/25 (2013.01); C12N 2500/38 (2013.01); C12N 2500/44 (2013.01); C12N 2500/90 (2013.01); C12N 2501/01 (2013.01); C12N 2501/105 (2013.01); C12N 2501/11 (2013.01); C12N 2501/115 (2013.01); C12N 2501/117 (2013.01); C12N 2501/155 (2013.01); C12N 2501/16 (2013.01); C12N 2501/33 (2013.01); C12N 2501/335 (2013.01); C12N 2501/385 (2013.01); C12N 2501/395 (2013.01); C12N 2501/40 (2013.01); C12N 2501/727 (2013.01); C12N 2501/91 (2013.01); C12N 2501/998 (2013.01); C12N 2501/999 (2013.01); C12N 2506/02 (2013.01); C12N 2506/45 (2013.01);
Abstract
Methods, kits, compositions, and systems are provided for culturing pluripotent stem cells to produce populations of cells comprising beta-like cells (e.g., pancreatic lineage, glucose-responsive, and/or insulin-producing). In particular, culture conditions are provided that result in the generation of beta-like cells from a starting culture of human pluripotent stem cells.